International Business Machines Corporation (IBM) was awarded a $7,081,492.15 delivery order against the Center for Biologics Evaluation and Research (CBER) Biologics Effectiveness and Safety (BEST) Initiative master indefinite delivery/indefinite quantity contract by the Department of Health and Human Services Food and Drug Administration. The delivery order is for the development of new and innovative methods for automated reporting to support CBER-regulated biologics and has a completion date of September 26, 2020. There is no set-aside designation. IBM will leverage its expertise in information technology and consulting to assist the FDA's CBER division, which regulates cell and gene therapies, blood, vaccines, and other biologics, in modernizing its reporting processes through September 2020.
Generated 2/24/24, 9:54 AM